期刊文献+

Ultrio和Ultrio plus 2种核酸试剂对献血者HCV RNA筛查的一致性分析 被引量:3

Comparison of Ultrio and Ultrio Plus NAT assays for screening of HCV RNA among blood donors
下载PDF
导出
摘要 目的追踪分析Ultrio和Ultrio plus 2种核酸试剂对抗-HCV阳性献血者血液标本筛查结果不一致的原因,并评价此2种核酸试剂检测HCV RNA的一致性。方法 6 254份ORTHO抗-HCV ELISA阴性及158份ORTHO抗-HCV ELISA阳性的无偿献血者血液标本,应用Procleix TIGRIS核酸检测系统的Ultrio、Ultrio plus试剂分别进行核酸筛查,对2种核酸试剂筛查HCV RNA结果不一致的献血者进行追踪,重新采集追踪标本补充Procleix Ultrio Elite、HCV Blot、HCV RNA定量检测,综合分析此2种核酸筛查试剂检测HCV RNA的临床灵敏度。结果 6 254份ORTHO抗-HCV ELISA阴性标本Ultrio、Ultrio plus试剂均未检出HCV RNA反应性。158份ORTHO抗-HCV ELISA阳性标本Ultrio反应性48例,Ultrio plus反应性51例,2种核酸试剂均为反应性47例。2种核酸试剂检测结果高度线性相关(Spearman相关系数rs=0.940,P<0.001),Kappa检验显示一致性极强(Kappa=0.940,P<0.001),配对卡方检验差异无统计学意义。6例核酸检测不一致标本分别为:2例Ultrio+/Ultrio plus-中1例HCV Blot阳性、1例HCV Blot可疑,1例HCV病毒核酸定量检测有结果;4例Ultrio-/Ultrio plus+标本中HCV Blot阳性3例、阴性1例,HCV病毒核酸定量检测3例有结果。追踪标本分析:1例Ultrio+/Ultrio plus-标本检测结果HCV Blot确证试验可疑,Ultrio Elite无反应性、HCV病毒核酸定量检测无结果;2例Ultrio-/Ultrio plus+追踪标本Ultrio Elite检测均无反应性,HCV Blot均阳性。结论 Ultrio与Ultrio plus核酸试剂检测HCV RNA一致性好,对临近检出限的低病毒载量标本均存在概率性检出。 Objective To analyze the performance of Ultrio plus and Ultrio for screening of HCV RNA by tracking samples with discordant nucleic acid test results in anti-HCV positive blood donors.Methods A total of 6254 ORTHO anti-HCV ELISA negative donor samples and 158 anti-HCV positive donor samples were tested by Ultrio and Ultrio plus on Procleix TIGRIS nucleic acid detection system. Blood donors with inconsistent HCV RNA results screened by two NAT reagents were followed up. The followed-up samples were collected again and retested by Procleix Ultrio Elite, HCV confirmatory test and quantitative detection of HCV RNA.The clinical sensitivity of two NAT reagents for detection of HCV RNA Was comprehensively analyzed.Results No HCV RNA was detected in 6254 ORTHO anti-HCV ELISA negative samples. There were 48 cases of Ultrio reactivity, 51 cases of Ultrio plus reactivity, and 47 cases of both nucleic acid reagents in 158 ORTHO anti-HCV ELISA positive samples. Good correlation between two reagents results(Spearman correlation coefficient RS=0.940, P<0.001). The Kappa statistic for results of two reagents was 0.940, indicating strong concordance(Kappa value=0.940, P<0.001). The McNemar-Bowker test revealed no statistical significance(McNemar-Bowker, P>0.05). Inconsistent sample analysis: Among 2 Ultrio+/Ultrio plus-samples, 1 HCV Blot confirmed test positive, 1 HCV Blot suspicious, 1 HCV virus nucleic acid quantitative test had result;1 HCV Blot confirmed test negative, 3 HCV Blot positive in 4 Ultrio-/Ultrio plus-samples. 3 HCV virus nucleic acid quantitative test had results. Follow-up sample analysis: 1 Ultrio+/Ultrio plus-samples HCV Blot was suspicious, while Ultrio Elite was negative, HCV virus nucleic acid quantitative hadn’t result. 2 Ultrio-/Ultrio plus + samples Ultrio Elite were non-reactive, and HCV Blot were positive.Conclusion Ultrio and Ultrio plus reagents have good consistency in detecting HCV RNA, and there are probabilistic detections for low viral load samples near the detection limit.
作者 张红 周龙 许晓绚 熊文 古醒辉 王立林 洪文旭 曾劲峰 ZHANG Hong;ZHOU Long;XU Xiaoxuan;XIONG Wen;GU Xinghui;WANG Lilin;HONG Wenxu;ZENG Jinfeng(Shenzhen Blood Center,Shenzhen 518035,China)
机构地区 深圳市血液中心
出处 《中国输血杂志》 CAS 2018年第12期1341-1344,共4页 Chinese Journal of Blood Transfusion
基金 深圳市科技创新委员会项目(JCYJ20160427145626702 JCYJ20170307092008192)
关键词 HCV RNA核酸检测 核酸筛查 概率性检出 HCV Blot确证 HCV RNA screening NAT probabilistic detections HCV Blot confirmatory assay
  • 相关文献

参考文献5

二级参考文献48

  • 1聂冬梅,王飞,尚桂芳,叶贤林,杨立新,周华.深圳市无偿献血者丙型肝炎检测结果回顾性分析[J].江西医学检验,2006,24(2):118-120. 被引量:3
  • 2Dodd R,Kurt Roth W,Ashford P,et al.Transfusion medicinandsafety.Biologicals,2009,37(1):62-70.
  • 3Glynn SA,Kleinman SH,Wright DJ,et al.International applicationof the incidence rate/window period model.Transfusion,2002,42(8):966-972.
  • 4Correll PK,Law MG,Seed CR,et al.Variant Creutzfeldt-Jakob dis-ease in Australian blood donors:estimation of risk and the impactof deferral strategies.Vox Sang,2001,81(1):6-11.
  • 5Dodd RY,Notari EPt,Stramer SL.Current prevalence and inci-dence of infectious disease markers and estimated window-periodrisk in the American Red Cross blood donor population.Transfu-sion,2002,42(8):975-979.
  • 6Gonzalez M,Regine V,Piccinini V,et al.Residual risk of transfusion-transmitted human immunodeficiency virus,hepatitis C virus,and hep-atitis B virus infections in Italy.Transfusion,2005,45(10):1670-1675.
  • 7Velati C,Romano L,Baruffi L,et al.Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood inItaly.Transfusion,2002,42(8):989-993.
  • 8Al Shaer L,Abdulrahman M,John TJ and Alhashimi A.Trends inprevalence,incidence,and residual risk of major transfusion-trans-missible viral infections in United Arab Emirates blood donors:im-pact of individual-donation nucleic acid testing,2004 through2009.Transfusion,2012,52(11):2300-2309.
  • 9Barreto CC,Sabino EC,Goncalez TT,et al.Prevalence,incidence,and residual risk of human immunodeficiency virus among commu-nity and replacement first-time blood donors in Sao Paulo,Brazil.Transfusion,2005,45(11):1709-1714.
  • 10Alvarez do Barrio M,Gonzalez Diez R,Hernandez Sanchez JM,et al.Residual risk of transfusion-transmitted viral infections in Spain,1997-2002,and impact of nucleic acid testing.Euro Surveill,2005,10(2):20-22.

共引文献35

同被引文献19

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部